Fast facts
| Founded | November 2003 |
| Ownership | Publicly traded on AiM of London Stock Exchange |
| Profile | Proximagen is a biotechnology company focused on drug development for diseases of the Central Nervous System (CNS). |
| Mission Statement | Discoveries for life™. We are committed to bringing novel drugs and innovative new treatments to CNS disorders as rapidly as possible, bringing new hope to the patients and value to our shareholders. |
| Pipeline | Proximagen's pipeline now comprises a board range of programmes derived from in-house discovery activities, outright purchase of assets, and purchases of assets through corporate acquisition on success-based terms. |
| Group companies | The Proximagen Group consists of Proximagen Limited,Cambridge Biotechnology Limited and Minister Pharmaceuticals plc. |
| Registered Address | 3rd Floor The Corner 91-93 Farringdon Road London EC1M 3LN United Kingdom Proximagen plc is registered in England and Wales with registration number 05333020 Proximagen's VAT number is 864 1401 41 |